DADC
ADAP

D.A. Davidson & Co’s Adaptimmune Therapeutics ADAP Stock Holding History

D.A. Davidson & Co’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,199
Closed -$64K – 1134
2018
Q4 		$64K Sell
11,199
-12,675
-53% -$93.5K ﹤0.01% 1071
2018
Q3 		$324K Sell
23,874
-25,434
-52% -$267K 0.01% 878
2018
Q2 		$585K Sell
49,308
-1,347
-3% -$16.8K 0.01% 645
2018
Q1 		$569K Sell
50,655
-1,427
-3% -$12.5K 0.01% 637
2017
Q4 		$348K Sell
52,082
-2,429
-4% -$18.8K 0.01% 789
2017
Q3 		$446K Buy
54,511
+18,500
+51% +$116K 0.01% 713
2017
Q2 		$161K Sell
36,011
-1,326
-4% -$6.93K ﹤0.01% 1049
2017
Q1 		$205K Buy
+37,337
New +$163K 0.01% 927
2016
Q3 		– Sell
-1,000
Closed -$8K – 2367
2016
Q2 		$8K Hold
1,000
– – ﹤0.01% 2008
2016
Q1 		$8K Hold
1,000
– – ﹤0.01% 1945
2015
Q4 		$12K Buy
+1,000
New +$9.79K ﹤0.01% 1850

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.A. Davidson & Co's ADAP Position: Q1 2019 in Review

D.A. Davidson & Co sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 11,199 shares — an estimated $64K sold.

D.A. Davidson & Co first reported a position in ADAP in Q4 2015 and held it in 11 quarters. The position peaked at $585K in Q2 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • D.A. Davidson & Co reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • D.A. Davidson & Co sold 11,199 Adaptimmune Therapeutics shares in Q1 2019, an estimated $64K.
  • D.A. Davidson & Co first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 11 quarters.
  • D.A. Davidson & Co's Adaptimmune Therapeutics position peaked at $585K in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on D.A. Davidson & Co's 13F filing for Q1 2019, filed 13 May 2019.